Search

Your search keyword '"Scarpelli, Giovanni"' showing total 11 results
Start Over Author "Scarpelli, Giovanni"
11 results on '"Scarpelli, Giovanni"'

3. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses

Author

Ferolla, Piero, Faggiano, A, Grimaldi, F, Ferone, D, Scarpelli, Giovanni, Ramundo, V, Severino, R, Bellucci, Mc, Camera, Lm, Angeletti, Gabriella, Angeletti, G, Colao, A., Ferolla, P, Faggiano, Antongiulio, Grimaldi, F, Ferone, D, Scarpelli, G, Ramundo, V, Severino, R, Bellucci, Mc, Camera, Lm, Lombardi, G, Angeletti, G, and Colao, A.

Subjects
Adult, Male, Lung Neoplasms, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Aged, Aged, 80 and over, Carcinoma, Neuroendocrine, Cell Differentiation, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Gastrointestinal Neoplasms, Humans, Middle Aged, Multiple Endocrine Neoplasia Type 1, Octreotide, Thymus Neoplasms, Treatment Outcome, Dose-Response Relationship, 80 and over, Hormonal, Carcinoma, Neuroendocrine, Drug
Abstract

In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects. AIM: The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WDNET patients with progressive disease at standard-dose interval. SUBJECTS AND METHODS: Twenty-eight patients followed for diagnosis and therapy of WDNET who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. RESULTS: The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40% and 60% of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of disease was obtained in 93% and objective response in 7%. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (30 vs 9 months, p

Published
2011

7. Well differentiated thoracic neuroendocrine tumors: clinical management and therapy

Author

Ferolla, Piero, Daddi, N, Scarpelli, Giovanni, Ascani, Stefano, Lemmi, A, Semeraro, A, Alpini, A, Avenia, Nicola, Giovenali, P, Ribacchi, Rodolfo, Bolis, Giovanni Battista, Lupattelli, Luciano, Puma, Francesco, Daddi, Giuliano, Angeletti, Gabriella, and Santeusanio, Fausto

Subjects
Carcinoid, Diagnosis, Neuroendocrine tumors, Therapy
Published
2007

10. Clinical behavior and prognosis of lymph-nodal Merkel cell carcinoma (MCC) in the absence of a primary tumor.

Author

Albertelli, Manuela, primary, Faggiano, Antongiulio, additional, Grimaldi, Franco, additional, Ameri, Pietro, additional, Palmieri, Giovannella, additional, Scarpelli, Giovanni, additional, Federico, Piera, additional, Bellevicine, Claudio, additional, Troncone, Giancarlo, additional, Grillo, Federica, additional, Minuto, Francesco, additional, Crino, Lucio, additional, Colao, Annamaria, additional, Ferone, Diego, additional, and Ferolla, Piero, additional

Published
2012
Full Text
View/download PDF

11. [Comorbility between anxiety and depression in patients with carcinoid tumors].

Author

Moretti P, Dennis JL, Stella A, Alpini A, Cotichelli P, Ferolla P, Scarpelli G, Quartesan R, and Piselli M

Subjects
Adult, Aged, Anxiety diagnosis, Anxiety epidemiology, Carcinoid Tumor metabolism, Comorbidity, Depression diagnosis, Depression epidemiology, Digestive System Neoplasms metabolism, Emotions, Female, Gastrointestinal Hormones metabolism, Humans, Incidence, Inpatients, Italy epidemiology, Male, Middle Aged, Prevalence, Psychiatric Status Rating Scales, Surveys and Questionnaires, Anxiety etiology, Carcinoid Tumor psychology, Depression etiology, Digestive System Neoplasms psychology
Abstract

Background: People who have malignant cancer are plagued with a variety of symptoms that often severely limit their lives. In the case of carcinoid tumors, symptoms of anxiety and depression are two manifestations often associated with disturbances produced by the tumor itself and the chemicals that the tumor secretes. The aim of this study was to compare the incidence of these symptoms for gastro-entero-pancreatic (GEP) tumors and non-gastro-entero-pancreatic (non-GEP)., Methods: Patients with GEP and patients with non-GEP completed the Hospital Anxiety and Depression Scale (HADS). HADS and all of its subscales were analyzed., Results: Patients with GEP tended to have higher average total scores on the HADS-D than those with non-GEP (p<0.08), and items in which the difference between GEP and non-GEP were statistically significant were anhedonia (p<0.05), a reduced ability to laugh and have fun (p<0.05), and the feeling of hopelessness (p<0.05). No significant differences emerged, however, in HADS-T and HADS-A scores., Conclusions: On the basis of these findings, patients with GEP are affected more than patients with non-GEP with increased levels of depressive and anxiety symptoms. What is difficult to determine, however, is whether these symptoms are related to hormone overproduction, or whether they are related to tumor-related emotional distress.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results